Patent intelligence · US
US 9687441
Compositions for use with a fascia tissue treatment device to reduce cellulite
Compositions for use with a fascia tissue treatment device to reduce cellulite
Patent details — US 9687441
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 27, 2017
- Expiration
- Jun 22, 2037
- Claims
- 12
- CPC classes
- A61K, A61K2800/5922, A61K8/11, A61K8/347
Quick answer
US 9687441 (Compositions for use with a fascia tissue treatment device to reduce cellulite) is held by Ashley Diana Black International Holdings, LLC. Status: granted. Granted Jun 27, 2017. Expires Jun 22, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2800/5922, A61K8/11, A61K8/347, A61K8/375, A61K8/678
More from Ashley Diana Black International Holdings, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 9687441?
US 9687441 (Compositions for use with a fascia tissue treatment device to reduce cellulite) is held by Ashley Diana Black International Holdings, LLC. Status: granted. Granted Jun 27, 2017. Expires Jun 22, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9687441?
Ashley Diana Black International Holdings, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 9687441 expire?
Our index shows an expiration date of Jun 22, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.